Arbutus Biopharma Corporation (ABUS)
Develops experimental medicines to treat chronic hepatitis B virus infections.
$4.41+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+34.9%
The outlook
Arbutus Biopharma has strong analyst backing, with both covering analysts rating it a Strong Buy and an average price target about 17% above the current level. The stock is trading below both its 50- and 200-day moving averages, though it sits midway through its 52-week range. The overall sentiment leans bullish despite the near-term technical weakness.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range54% of the way from its 52-week low to high
Price targetAvg target +17% vs current price
Analyst price target
~12-month · 2 analysts$5.16average target+17.0% vs now
Now $4.41
Low $4.84High $5.47
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$871.1M
52-wk high
$5.38
52-wk low
$3.26
50-day avg
$4.51
200-day avg
$4.45
Trailing P/E
5.3